Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Tovorafenib by Day One Biopharmaceuticals for Craniopharyngioma: Likelihood of Approval
Tovorafenib is under clinical development by Day One Biopharmaceuticals and currently in Phase II for Craniopharyngioma. According to GlobalData, Phase...
Data Insights
Pimasertib hydrochloride by Day One Biopharmaceuticals for Solid Tumor: Likelihood of Approval
Pimasertib hydrochloride is under clinical development by Day One Biopharmaceuticals and currently in Phase II for Solid Tumor. According to...